Cargando…

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

BACKGROUND AND OBJECTIVE: Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is approved in the United S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zahir, Hamim, Greenberg, Jonathan, Shuster, Dale, Hsu, Ching, Watanabe, Kengo, LaCreta, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652259/ https://www.ncbi.nlm.nih.gov/pubmed/36264536 http://dx.doi.org/10.1007/s40262-022-01172-9

Ejemplares similares

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
por: Leil, T A, et al.
Publicado: (2014)

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study
por: Tachibana, Masaya, et al.
Publicado: (2018)

Anticoagulation in COVID-19: DDI Perspective
por: Khiali, Sajad, et al.
Publicado: (2020)

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial
por: Van De Sande, Michiel, et al.
Publicado: (2021)

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
por: Garimella, Tushar, et al.
Publicado: (2017)

Ddi1 is a ubiquitin-dependent protease
por: Yip, Matthew C. J., et al.
Publicado: (2020)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model
por: Leil, T A, et al.
Publicado: (2014)

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
por: Hong, Ying, et al.
Publicado: (2021)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases
por: Mótyán, János András, et al.
Publicado: (2020)

Hepatoma Formation in ddY Mice with Chronic Schistosomiasis japonica
por: Amano, Teruaki, et al.
Publicado: (1988)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

ReaDDy 2: Fast and flexible software framework for interacting-particle reaction dynamics
por: Hoffmann, Moritz, et al.
Publicado: (2019)

ReaDDy - A Software for Particle-Based Reaction-Diffusion Dynamics in Crowded Cellular Environments
por: Schöneberg, Johannes, et al.
Publicado: (2013)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination
por: Elu, Nagore, et al.
Publicado: (2019)

Pacemaker-induced tachycardia in a DDI-programmed ICD: What is the mechanism?
por: Jafri, Haseeb, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects
por: Zhou, Chen, et al.
Publicado: (2021)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cn6d5alnhkfqb4u8lkp2er8or1